GENEVA, Nov. 4 -- SAMSUNG MEDICAL FOUNDATION (29, Saemunan-roJongno-guSeoul 03181), (의) 삼성의료재단 (서울특별시종로구새문안로 29), ENDOCURA INC. (404, 8, Gyeonggyojang-gilJongno-guSeoul 03181), 주식회사 엔도큐라 (서울특별시종로구경교장길 8, 404호) filed a patent application (PCT/KR2025/005522) for "PHARMACEUTICAL COMPOSITION FOR TUMOR VASCULAR DISRUPTION" on Apr 24, 2025. With publication no. WO/2025/226040, the details related to the patent application was published on Oct 30, 2025.
Notably, the paten...